05059166 is referenced by 367 patents and cites 6 patents.

Intra-arterial stents are frequently used subsequent to balloon angioplasty to maintain arterial patency. The most frequent cause for failure to maintain patency is the rapid growth of the injured arterial tissue through the openings in the stent, which rapid growth is called "intimal hyperplasia." Since irradiation from a radioisotope source is capable of selectively inhibiting the growth of hyperproliferating cells as compared with normal cells, a radioisotope material which forms part of the stent can be used to decrease the rate of arterial reclosure. The radioisotope could be placed inside the stent, alloyed into the metal from which the stent is made, or preferably, it can be coated onto the stent's exterior surface. Beta emitting radioisotopes having a half-life between 1 and 100 days would be best suited as a stent coating because of their comparatively short range of action within human tissue, and because of their comparatively short half-life. An anti-thrombogenic coating placed on the outer surface of the radioisotope stent would further reduce arterial reclosure by decreasing stent thrombogenicity.

Title
Intra-arterial stent with the capability to inhibit intimal hyperplasia
Application Number
7/448691
Publication Number
5059166
Application Date
December 11, 1989
Publication Date
October 22, 1991
Inventor
Tim A Fischell
Los Altos
CA, US
Robert E Fischell
Dayton
MD, US
Assignee
Medical Innovative Technologies R & D Partnership
MD, US
IPC
A61N 5/00
View Original Source